Abstract 27P
Background
There is growing evidence that elevated neutrophil to lymphocyte ratio (NLR) is associated with poor treatment response and survival outcomes in breast cancer. Also, standardized uptake value (SUV) of 18F-fluorodeoxyglucose (FDG) PET has been applied as a prognostic factor in breast cancer. In this study, we investigated the treatment response and survival outcomes according to NLR and SUV in breast cancer patients who received neoadjuvant chemotherapy (NAC).
Methods
Baseline NLR and SUVmax of 18F-FDG PET was retrospectively analyzed in 273 breast cancer patients who were received NAC followed by surgery from January 2007 to June 2018. Baseline NLR is calculated as absolute neutrophil count divided by absolute lymphocyte count from blood samples taken before initiation of NAC. Of the total, 101 patients underwent 18F-FDG PET after 3-4 cycles of NAC. The ΔSUVmax, the percentage reduction between SUVmax at baseline and after 3-4 cycles of NAC, was obtained from these patients. NLR and ΔSUVmax was classified as high and low relative to the median values (NLR: 2.04 and ΔSUVmax: 73.3%).
Results
The patients with pathologic complete response (pCR) had lower NLR and higher ΔSUVmax. Among all patients, high NLR was associated poor survival outcomes in terms of disease-free survival (DFS, adjusted HR 2.42; 95% Cis, 1.23-4.78; P = 0.011) and overall survival (OS, adjusted HR 1.53; 95% Cis, 1.19-1.97; P = 0.001), respectively. In 101 patients with data for early change of SUVmax, the high NLR (adjusted HR 3.20; 95% CIs, 1.29-7.89; P = 0.015) and low ΔSUVmax (adjusted HR 3.20; 95% CIs, 1.29-7.89; P = 0.015) were an independent prognostic factor for poor RFS. When patients were categorized into four groups according to NLR and ΔSUVmax, the patients with high NLR and low ΔSUVmax had significantly poor RFS (adjusted HR 8.71; 95% CIs, 1.87-40.64; P = 0.006) compared to those with low NLR and high ΔSUVmax.
Conclusions
Both the baseline NLR and ΔSUVmax were associated with treatment response and prognosis in breast cancer patients who received NAC. Moreover, we identified that metabolic non-responders with degraded immune system had a worst impact on survival outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract